# Betta Pharmaceuticals Co., Ltd. clinical trials: 79 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 79 trials with Betta Pharmaceuticals Co., Ltd. as lead sponsor, 14 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Betta Pharmaceuticals Co., Ltd.: 79 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/betta-pharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 79
- Recruiting or not yet: 14
- Read on: November 19, 2026

## Trials

The 25 newest of 79, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 9, 2026 | NCT07809815 | Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | DDI (Drug-Drug Interaction) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809815) |
| September 9, 2026 | NCT07809802 | Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Hepatic Impairment (HI) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809802) |
| September 9, 2026 | NCT07809789 | Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | DDI (Drug-Drug Interaction) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809789) |
| September 8, 2026 | NCT07806604 | Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer | Betta Pharmaceuticals Co., Ltd. | Observational | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 2,572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806604) |
| March 4, 2026 | NCT07448116 | Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. | Betta Pharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Solid Advanced Tumor | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448116) |
| February 27, 2026 | NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Betta Pharmaceuticals Co., Ltd. | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435038) |
| September 18, 2025 | NCT07181499 | Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | Betta Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | NSCLC, Adjuvant Drug Therapy, EGFR | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181499) |
| March 20, 2025 | NCT06885840 | Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | Betta Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Non-Small Cell Lung Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885840) |
| October 15, 2024 | NCT06641609 | A Phase I Study of CFT8919 in Patients With Advanced NSCLC | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Non-Small Cell Lung Cancer With EGFR Mutation | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641609) |
| July 9, 2024 | NCT06492525 | A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492525) |
| September 18, 2023 | NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | Betta Pharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06041776) |
| August 29, 2023 | NCT06015568 | Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Not yet recruiting | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06015568) |
| May 22, 2023 | NCT05869240 | BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors | Betta Pharmaceuticals Co., Ltd. | Phase 1/2 | Unknown | Solid Tumor | 388 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05869240) |
| May 6, 2023 | NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05843305) |
| March 29, 2023 | NCT05789602 | A Study of BPI-460372 in Advanced Solid Tumor Patients | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05789602) |
| June 27, 2022 | NCT05433480 | A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer | Betta Pharmaceuticals Co., Ltd. | Phase 3 | Unknown | Breast Cancer | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433480) |
| May 11, 2022 | NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05369312) |
| April 22, 2022 | NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | Betta Pharmaceuticals Co., Ltd. | Phase 3 | Unknown | Non-small Cell Lung Cancer | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05341583) |
| April 22, 2022 | NCT05341570 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05341570) |
| April 22, 2022 | NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor, Lymphoma, NSCLC, HCC | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05341557) |
| April 15, 2022 | NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | Betta Pharmaceuticals Co., Ltd. | Phase 1/2 | Unknown | Non-small Cell Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05329298) |
| April 7, 2022 | NCT05316259 | A Food-Effect Study of BPI-16350 in Healthy Subjects | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05316259) |
| April 7, 2022 | NCT05315180 | A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Malignant Neoplasms, Metastatic Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05315180) |
| March 31, 2022 | NCT05302843 | A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors | Betta Pharmaceuticals Co., Ltd. | Phase 1 | Unknown | Metastasis, Neoplasm | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05302843) |
| August 17, 2021 | NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | Betta Pharmaceuticals Co., Ltd. | Phase 2 | Unknown | Non-Small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05007938) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 1/2 | 7 |
| Phase 2 | 24 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 8 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 45 |
| Completed | 17 |
| Recruiting | 12 |
| Not yet recruiting | 2 |
| Suspended | 1 |
| Terminated | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 36 |
| Brain Neoplasms | 5 |
| Pancreatic Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Adenocarcinoma | 4 |
| Psoriasis | 3 |
| Lung Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
| Nasopharyngeal Carcinoma | 1 |
| Esophageal Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Carcinoma, Renal Cell | 1 |
| von Hippel-Lindau Disease | 1 |
| Neoplasms | 1 |
| Lymphoma | 1 |
| Breast Neoplasms | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
- [Jewelry manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-manufacturers/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
